Key insights
- Eli Lilly is leveraging future UK investment to pressure the NHS for higher drug prices and changes to rebate schemes. While primarily impacting the UK healthcare system, this could have a slightly negative influence on US equities as it highlights potential pricing pressures and negotiation challenges for pharmaceutical companies globally.
Investing.com -- Eli Lilly (NYSE:LLY) will only resume investment in the UK if the government agrees to regular increases in NHS drug prices and phases out a multibillion-pound rebate scheme, according to Patrik Jonsson, president of Lilly’s international businesses.
Jonsson told the Financial Times that the company is in talks with UK ministers and feels optimistic about reaching an agreement by the summer for Britain to pay more for its medicines.
The discussions will also explore innovative pricing plans that would link payments for anti-obesity medication to whether patients become well enough to return to work as a result of their treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.